Roche's Actem­ra wins ap­proval for hos­pi­tal­ized Covid pa­tients

Roche up­grad­ed its emer­gency use au­tho­riza­tion for Actem­ra in cer­tain hos­pi­tal­ized Covid-19 pa­tients to a full FDA ap­proval, the com­pa­ny an­nounced Wednes­day, as cas­es climb in the US.

The ap­proval comes rough­ly a year and a half af­ter the mon­o­clon­al an­ti­body treat­ment re­ceived an EUA to treat hos­pi­tal­ized pa­tients 2 years and old­er who are al­so re­ceiv­ing sys­temic cor­ti­cos­teroids and re­quire sup­ple­men­tal oxy­gen, ven­ti­la­tion or life sup­port. While the ap­proval is on­ly for adults, Actem­ra will con­tin­ue to be avail­able for younger pa­tients un­der the EUA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER